Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
17 Setembro 2024 - 5:01PM
Business Wire
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle
disease biopharmaceutical company, today announced that members of
the management team will hold a live webcast to discuss top-line
data of EDG-7500 from the Phase 1 trial in healthy subjects and the
single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with
obstructive HCM on Thursday, September 19, 2024, at 8:30 am ET. The
team will be joined by CIRRUS-HCM investigator, Anjali T. Owens,
M.D., Medical Director, Center for Inherited Cardiac Disease,
Associate Professor of Medicine, University of Pennsylvania, who
will share her perspective of EDG-7500 and HCM. An accompanying
slide presentation will also be available. To register for the live
webcast and replay, please visit the Edgewise events page.
About EDG-7500
EDG-7500 is a novel oral, selective, cardiac sarcomere
modulator, specifically designed to slow early contraction velocity
and address impaired cardiac relaxation associated with
hypertrophic cardiomyopathy (HCM) and other diseases of diastolic
dysfunction. To learn more about CIRRUS-HCM, visit
clinicaltrials.gov, NCT06347159 (Phase 2).
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease
biopharmaceutical company developing novel therapeutics for
muscular dystrophies and serious cardiac conditions. The Company’s
deep expertise in muscle physiology is driving a new generation of
novel therapeutics. Sevasemten is an orally administered skeletal
myosin inhibitor in late-stage clinical trials in Becker and
Duchenne muscular dystrophies. EDG-7500 is a novel cardiac
sarcomere modulator for the treatment of hypertrophic
cardiomyopathy and other diseases of diastolic dysfunction,
currently in Phase 2 clinical development. The entire team at
Edgewise is dedicated to our mission: changing the lives of
patients and families affected by serious muscle diseases. To learn
more, go to: www.edgewisetx.com or follow us on LinkedIn, X,
Facebook and Instagram.
This press release contains hyperlinks to information that is
not deemed to be incorporated by reference into this press
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240917581066/en/
Edgewise Contacts Investors: Michael Carruthers,
Chief Financial Officer ir@edgewisetx.com
Media: Maureen Franco, VP Corporate Communications
media@edgewisetx.com
Edgewise Therapeutics (NASDAQ:EWTX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Edgewise Therapeutics (NASDAQ:EWTX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
